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Dof dementia. Emerging evidence suggests that systemic inflammation also contributes to disease pro-
gression.
Methods: The ability of systemically administered lipopolysaccharide (LPS - 500 mg/kg) to effect
acute and chronic behavioural changes in C57BL/6 and P301S tauopathy micewas assessed. Markers
of pathology were assessed in the brain and spinal cord.
Results: P301S mice display regional microgliosis. Systemic LPS treatment induced exaggerated
acute sickness behaviour and motor dysfunction in P301S mice compared with wild-type controls
and advanced the onset and accelerated chronic decline. LPS treatment was associated with increased
tau pathology 24 hours after LPS injection and spinal cord microgliosis at the end stage.
Discussion: This is the first demonstration that a single systemic inflammatory episode causes exag-
gerated acute functional impairments and accelerates the long-term trajectory of functional decline
associated with neurodegeneration in a mouse model of human tauopathy. The findings have rele-
vance to management of human dementias.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Tau; Acute illness; Delirium; Systemic inflammation; Dementia; Alzheimer’s disease; Microglia; LPS; IL-11. Introduction
Neuroinflammation is a consistent hallmark across neuro-
degenerative diseases and plays a pivotal role in the pathobi-
ology of dementias. Genetic discoveries link Alzheimer’s
disease (AD) risk and inflammatory genes (CLU, CR1, PIC-re no conflicts of interest to disclose.
thor. Tel.: 353-01-896-3964.
author. Tel.: 0131 242 9519.
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increases risk and rate of progression of dementia [8–10].
A prospective cohort study of mild-to-severe AD revealed
that acute systemic inflammatory events doubled the rate
of cognitive decline [11]. The mechanisms underlying sys-
temic inflammation-mediated cognitive decline are unclear
but interaction with primed microglia in the context of de-
mentia may lead to acute deficits, including delirium, and
long-term sequelae [12,13].
Others have shown that systemic inflammation exacer-
bates tau pathology. Repeated lipopolysaccharide (LPS)imer’s Association. This is an open access article under the CC BY-NC-ND
gh from ClinicalKey.com by Elsevier on November 05, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
M. Torvell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 579-591580injection in 3xTg-AD mice did not affect amyloid pathology
but dramatically increased microglial burden, IL-1b expres-
sion, and tau hyperphosphorylation [14]. The same regime
exacerbated tau pathology in wild-type mice, while in
hTau mice crossed to fractalkine (CX3CR1) knockouts
(hTau-CX3CR12/2), LPS dose-dependently increased tau
phosphorylation, suggesting it was microglia-mediated
[15]. Intracerebral LPS in rTg4510 tau mice increased
expression of microglial markers CD45, Arg-1, and YM1
and exacerbated tau pathology [16].
None of these studies tested impact of systemic inflam-
mation on functional decline in the respective models.
Accelerated decline was previously demonstrated in a prion
disease model; wherein primedmicroglia produced exagger-
ated responses to LPS challenge, increasing microglial IL-
1b, which contributes to sickness behaviour, acute working
memory deficits, and accelerated progression of disease
[12,17]. Recent studies in humans and mice support the
hypothesis that the impact of systemic inflammation is
influenced by the extent of underlying pathology [18].
In the present study, we investigate acute and chronic func-
tional impacts of a single systemic inflammatory episode in the
P301S tauopathy mouse model characterized by hyperphos-
phorylation and accumulation of misfolded tau, regional
neuronal loss, astrogliosis, and microgliosis [19–21]. P301S
tau mice or C57BL/6 controls were injected intraperitoneally
with LPS and acute and chronic consequences were
monitored. The findings demonstrate robust acute and
chronic functional impacts of LPS, and increased AT81-tau
pathology, which is independent of microglial priming but
dependent on the underlying disease stage.2. Methods
2.1. Animals
All procedures complied with UK Animals Scientific
Procedures Act 1986 and local regulations. Animals were
group-housed in environmentally enriched cages, with a
12-hour light/dark cycle, and access to food and water ad li-
bitum. C57BL/6 animals were sacrificed at 8, 12, and
20 weeks and P301S at 8, 9, 10, 11, 12, 16, and 20 weeks,
and in LPS studies either 24 hours after injection or at 22
weeks of age for immunohistochemistry.
2.2. LPS injections
Micewere injected intraperitoneally with 500 mg/kg lipo-
polysaccharide (LPS; Salmonella enterica, Sigma) or equiv-
alent volume of saline. The chosen dose elicited a significant
sickness and hypothermic response [22].
2.3. Behavioural tasks
Horizontal bar task: Mice were assessed weekly to
establish baseline, and at 1 and 24 hours before and 6
and 24 hours after injection (10 or 16 weeks) and 36Downloaded for Anonymous User (n/a) at The University of Edinbur
For personal use only. No other uses without permission. Chours after (16 weeks). Time taken for the mouse to either
reach the platform or fall from the bar was converted to a
score between 1 and 10 (Table 1). A maximum of 60 sec-
onds was allowed to complete the task. Each mouse
completed 3 trials per session and an average score was
calculated.
Open field: Mice were tested 24 hours before and 4 hours
and 24 hours after injection. Distance travelled was recorded
for each mouse, expressed as percentage of distance trav-
elled by saline controls and averaged for each group.
2.4. Immunostaining and histology
Animals were humanely euthanized with sodium pento-
barbitone (Euthatal) and perfused with cold PBS and 4%
paraformaldehyde. Brains and spinal cords (c5–c7) were
removed, postfixed in 4% paraformaldehyde, cryoprotected
in 25% sucrose, and then cryosectioned coronally at 25 mm
and 16 mm, respectively. Cresyl-violet staining to identify
neuronal cell bodies was performed after serial dehydration
in alcohol. Antibodies used for immunostaining are listed in
Table 2.
2.5. Immunofluorescence
Sections were rehydrated in 1% PBS, blocked, and per-
meabilized with 3% normal serum (NS, Vector Labora-
tories), 0.2% Triton-X100 (Tx; Sigma) where required, in
PBS for 1 hour. Primary antibodies were applied in the
same solution, overnight, slides washed, and incubated
with biotinylated secondary antibodies in PBS/1%NS for
1.5 hours, followed by streptavidin-conjugated tertiary anti-
body in PBS containing bis-benzamide (1:4000, Sigma Al-
drich) for 1.5 hours.
2.6. Diaminobenzidine staining
Nonspecific peroxidase activity was quenched with 1%
H2O2 in methanol. For antigen retrieval, slides were incu-
bated in citric acid (10mM, pH 6) for 10 minutes. Sections
were washed, blocked with PBS/10%NS for 1 hour, and
incubated with primary antibodies in PBS/10%NS over-
night, then with biotinylated secondary antibody, ABC com-
plex, and diaminobenzidine (DAB).
2.7. Quantitative analysis
Motor cortex superficial layers were imaged 0.75–
1.25mm from midline of sections, 0.5–2.3mm rostral to
bregma [23] using a Zeiss-A1 microscope with AxioVision
4.8 software. Cortical NeuN1-, cresyl-violet1-, GFAP1-,
and IBA11-cells were counted in at least 4 sections/animal.
A standard grid was drawn, cells counted up to 150mm depth
and expressed as cells/mm2. DAB-stained GFAP1-cell
counts were conducted in spinal cord lamina 9 in a
400mm ! 200 mm grid. Stitched brightfield images of the
whole IBA1 DAB-stained spinal cord were generated usinggh from ClinicalKey.com by Elsevier on November 05, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Table 1
Horizontal bar score
Score Time to fall (s) Score Time to platform (s)
0 0–5 10 0–5
1 6–10 9 6–10
2 11–20 8 11–20
3 21–40 7 21–30
4 41–59 6 31–59
5 60 5 60
M. Torvell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 579-591 581the Panavision tool in AxioVision. IBA11-cell counts were
conducted in a 200 mm ! 200 mm grid positioned over
ventral horn lamina 9.
2.8. Automated analyses
ImageJ/Fiji software [24,25] was used for automated
image analysis. A macro was used to batch process
images; steps were as follows: (1) subtract background; (2)
impose intensity threshold; (3) create binary mask; (4)
select area of interest; (5) count objects. Parameters were
determined by iterative optimization on randomly selected
images before batch processing.
2.9. ELISA and qPCR
C57BL/6 and P301Smicewere euthanized at 16 weeks of
age, 4 hours after injection with LPS or saline. Serum and
tissue were harvested. IL-1b and TNF-a serum levels were
quantified by ELISA (DuoSet; R&D Systems) according
to manufacturer’s protocols. For RNA isolation, 20–40 mg
cortex and spinal cord samples (c5–c7) were lysed and ho-
mogenized in QIAzol Lysis Reagent (79306, Qiagen). Total
RNAwas extracted using Qiagen RNeasyMini Kit; TURBO
DNA-freeKit (Ambion Life Technologies) was used to re-
move DNA contamination. Thermo Scientific DyNAmo
cDNA Synthesis Kit was used for reverse transcription.
Thermo Scientific DyNAmo Flash SYBR Green qPCR Kit
was used in a 96-well format with 15 ml reaction volume
for quantitative (Q)-PCR (10 minutes at 95C followed by
40 cycles of 10 seconds at 95C, 40 seconds at 60C, 30 sec-Table 2
Antibodies used
Antibody Cat #
Moue monoclonal anti-NeuN MAB
Rabbit polyclonal anti-GFAP (glial fibrillary acidic protein) Z033
Rabbit polyclonal anti-IBA1 MP-2
Goat polyclonal anti-IBA1 Ab50
Mouse monoclonal anti-phospho-tau (AT8)
Goat anti-rabbit IgG (H1L) biotinylated B277
Donkey anti-goat IgG (H1L) biotinylated A160
Horse anti-mouse/rabbit IgG (H1L) biotinylated BA-1
Streptavidin conjugated Alexa 488 S323
Streptavidin conjugated Alexa 568 S112
Goat anti-rabbit IgG (H1L) Alexa Fluor 488 A110
Goat anti-mouse IgG (H1L) Alexa Fluor 568 A110
Downloaded for Anonymous User (n/a) at The University of Edinbur
For personal use only. No other uses without permission. Conds at 72C). Primers were designed (across introns where
possible) using Primer Express software (Applied Bio-
systems). Primer and probe sequences are shown in
Table 3. Assays were quantified using a relative standard
curve and normalized to ribosomal RNA 18S expression.
Relative abundance of mRNA in groups was calculated by
the comparative CT method [26].2.10. Statistics
Mixed-effects linear regression (LR) with random inter-
cept for animal ID was used for within-time-point compari-
son of P301S with C57BL/6 mice (immunostaining,
histology, and qPCR). To investigate the trajectory of
increasing pathology and decline in horizontal bar perfor-
mance, an additional dummy variable was created for “age
in weeks” to recenter data. For LPS studies, an additional
term for LPS treatment was used for comparison of
C57BL/6 and P301S mice treated with either saline or
LPS. Custom hypothesis tests were used to generate esti-
mated means and SEMs for graphs. An interaction term
was generated to determine whether LPS had a greater effect
on P301S mice than controls. This analysis was used for
ELISA, qPCR, immunostaining, and within-time-point
open-field and acute horizontal bar data. Piecewise LR
was used with random intercept for ID to compare the longi-
tudinal trajectory of horizontal bar performance of the
groups.3. Results
3.1. Progressive neuronal loss in superficial motor cortex
and spinal cord of P301S mice
We sought to define the temporal pathological and behav-
ioural trajectory of disease progression to determine optimal
points to induce systemic inflammation. Noting earlier find-
ings of cortical neuronal loss [19], we undertook cresyl-vio-
let1-counts in motor cortex superficial layers at 8, 9, 10, 11,
12, 16, and 20 weeks of age (Fig. 1A–E). Neuronal density of
control mice was unchanged across all ages. Cresyl1-cellDilution Origin
377B 1:400 Merck Millipore
4 1:1000 DAKO
90-CR05 1:1000 A. Menarini Diagnostics
76 1:1000 AbCam
1:1000 Autogen Bioclear
0 1:1000 Thermo Fisher Scientific
03 1:1000 Thermo Fisher Scientific
400 1:200 Vector Laboratories
54 1:1000 Thermo Fisher Scientific
26 1:1000 Thermo Fisher Scientific
08 1:1000 Thermo Fisher Scientific
04 1:1000 Thermo Fisher Scientific
gh from ClinicalKey.com by Elsevier on November 05, 2019.
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Table 3
Primers supplied by Sigma (Poole, UK)
Target Accession no. Forward Reverse
18S NR_003278.3 50- CCCAGTAAGTGCGGGTCAT-30 50- CCGAGGGCCTCACTAAACC-30
Axl NM_001190974.1 50-TGAAGCCACCTTGAACAGTC-30 50-GCCAAATTCTCCTTCTCCCA-30
Clec7a NM_020008.3 50-CCCAACTCGTTTCAAGTCAG-30 50-AGACCTCTGATCCATGAATCC-30
Il1b NM_008361.4 50- TGCCACCTTTTGACAGTGATG-30 50- TGATGTGCTGCTGCGAGATT-30
Itgax NM_021334 50-CTGGATAGCCTTTCTTCTGCTG-30 50-GCACACTGTGTCCGAACTC-30
Tyrobp NM_011662.2 50-CGTACAGGCCCAGAGTGAC-30 50-CACCAAGTCACCCAGAACAA-30
M. Torvell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 579-591582density in P301S mice was significantly reduced compared
with controls from 11 weeks onward (Fig. 1E). As the domi-
nant motor phenotype of P301S mice is progressive hind-
limb paralysis due to ventral spinal cord motor neuron
loss, we next quantified neuronal loss in spinal cord lamina
9; significant loss of NeuN1-cells was apparent at 20 weeks
(Fig. 1F–J).
GFAP quantification for astrogliosis in the cortex or spi-
nal cord showed stable expression in C57BL/6 mice across
all ages studied. There was significant cortical astrogliosis
in P301S mice even at 8 weeks of age compared with con-
trols. Mixed-effects LR from 8 to 20 weeks of age revealed
progressive cortical astrogliosis, with average increase of
10.4 GFAP1-cells/mm2/week (P , .001; 95% CI 6.2 to
14.6; Fig. 1K–O). Astrogliosis in the ventral horn of the spi-
nal cord was elevated in P301S mice compared with controls
at 8 weeks and showed progression at 19.9 cells/mm2/week
(P , .001; 95% CI 14.2 to 25.; 6Fig. 1P–T).
3.2. P301S mice display regional heterogeneity of
microgliosis
Despite accumulation of hyperphosphorylated tau,
neuronal loss, and astrogliosis in the motor cortex, quantifi-
cation of IBA11-cells showed no difference in microglial
numbers in motor cortices of controls versus P301S mice
at any time point (Fig. 2A–E); however, there was progres-
sive microgliosis, associated with altered morphology, in
spinal cord lamina 9 of P301S mice, significant compared
with controls from 10 weeks of age (Fig. 2F–J). Microglial
activation status was examined by qPCR for markers of
priming and density (Fig. 2K). Motor cortex Itgax (cd11c)
mRNA levels were elevated (1.8-fold) in P301S mice rela-
tive to controls at 16 weeks but there were no significant dif-
ferences in Axl, Tyrobp, or Clec7a. By contrast, all
microglial activation markers were significantly elevated
in P301S spinal cords compared with controls: Axl (1.4-
fold); Tyrobp (1.9-fold); Itgax (14.9-fold); Clec7a (5.8-
fold), demonstrating regional heterogeneity of microgliosis
in P301S mice (Fig. 2K).
3.3. Defining disease progression using horizontal bar
performance
Noting that P301S mice develop progressive hind-limb
paralysis [20], we identified the horizontal bar task asDownloaded for Anonymous User (n/a) at The University of Edinbur
For personal use only. No other uses without permission. Coptimal to evaluate disease progression. Motor function of
control mice remained constant throughout the experiment,
whereas P301S mice exhibited a stable phase between 10
and 15 weeks and a declining phase between 15 and
21 weeks (20.9 D points/week; P , .001; 95% CI 21.1 to
20.8; Fig. 3A).
3.4. LPS injection caused exaggerated acute behavioural
and pathological responses in P301S mice
To assess the influence of underlying disease stage on the
impact of acute systemic inflammation, LPS was given i.p.,
either early (10 weeks), immediately preceding demon-
strable neuronal loss in P301S mice, or late (16 weeks), at
the point of inflection in the functional decline curve
(Fig. 3A), when neuronal loss, astrogliosis, and microgliosis
were already established. Both C57BL/6 and P301S mice
showed reduced locomotor activity in open field at 4 hours
after LPS injection, but while C57BL/6 mice completely
recovered by 24 hours, P301S mice showed persistently
reduced locomotor activity (w50% when injected at 10 or
16 weeks vs.w95% in C57BL/6; Fig. 3B). Because effects
of treatments at 10 and 16 weeks were statistically indistin-
guishable on all behavioural tasks, at every time point as-
sessed for C57BL/61saline, C57BL/61LPS, and
P301S1saline, these 10- and 16-week groups were pooled
in these 3 cases (for nonpooled data, see Supplementary
data).
3.5. LPS injection causes an exaggerated deficit in
horizontal bar performance of P301S mice
P301S mice showed exaggerated acute deficits in hori-
zontal bar performance in the hours after LPS injection in
an age-dependent manner (Fig. 3C). Before injection at
either 10 or 16 weeks of age, there was no difference in per-
formance between groups. Saline injection had no effect on
acute performance in P301S or C57BL/6 mice regardless of
age at injection (Fig. 3C); LPS injection had marginal influ-
ence on performance in C57BL/6 mice 6 hours after injec-
tion (Fig. 3C) but robustly impaired task performance of
P301S mice when injected at 10 or 16 weeks (Fig. 3C).
P301S mice injected at 16 weeks took longer to recover
than those injected at 10 weeks, suggesting that progressive
tau pathology increased vulnerability to these acute deficits
(Fig. 3C). Except for those from P301S1LPS, data from 10gh from ClinicalKey.com by Elsevier on November 05, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Fig. 1. Cell counts show progressive reduction in neuronal density in the superficial cortex and spinal cord accompanied by progressive astrogliosis: Repre-
sentative examples of cresyl-stained cortical tissue (A–D), NeuN-stained spinal cord (lamina 9 of c5–c7) (F–I), GFAP-stained cortical tissue (K–N), and
GFAP-stained spinal cord (lamina 9 of c5–c7), with in-lay to show morphology (P–S) from a 20-week-old C57BL/6 mouse and P301S mice at 8, 12, and
20 weeks. (E) Cresyl1-cell counts in the cortex (to subpial depth of 150 mm) indicate neuronal loss from 11 weeks onward (2514.2 Dcells/mm2; P 5 .036;
95% CI 2982.0 to 246.3). C57BL/6 n 5 4, P301S 8 wk n 5 5, 9 wk n 5 7, 10 wk n 5 7, 11 wk n 5 4, 12 wk n 5 5, 16 wk n 5 5, 20 wk n 5 5. (J)
NeuN1-cell counts demonstrate neuronal loss in lamina 9 at 20 weeks (2148.3 D cells/mm2; P , .001; 95% CI 2214.1 to 282.5). C57BL/6 n 5 13,
P301S numbers as above. (O) GFAP1 cell counts in the motor cortex (to subpial depth of 150 mm) showed astrogliosis in P301S mice from 8 weeks onward.
C57BL/6 n5 8, P301S 8 wk n5 5, 9 wk n5 5, 10 wk n5 5, 11 wk n5 5, 12 wk n5 5, 16 wk n5 5, 20 wk n5 4. (T) GFAP1 cell counts in lamina 9 of the
spinal cord showed astrogliosis at 8 weeks (mixed-effects LR indicated by *P , .05, **P , .005, ***P , .0001). Evaluation of time course confirmed that
astrogliosis in the cortex and spinal cord was progressive. C57BL/6 n 5 8, P301S 8 wk n 5 4, 9 wk n 5 4, 10 wk n 5 3, 11 wk n 5 4, 12 wk n 5 5,
16 wk n 5 5 20 wk n 5 4. Dotted lines mark 150 mm subpial depth. Scale bars represent 100 mm, in-lay scale bar represents 25 mm. Analyses were by
mixed-effects LR; *P , .05, **P , .005, ***P , .0001. Abbreviation: LR, linear regression.
M. Torvell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 579-591 583and 16 weeks were pooled, as described previously, for
clarity of presentation. The statistical significance of effects
of LPS on horizontal bar performance in P301Smicewas not
dependent on pooling of data (for nonpooled data, see
Supplementary data).3.6. LPS injection caused comparable levels of peripheral
inflammation in P301S and control mice
To assess inflammatory status during LPS challenge
and whether challenge triggered de novo pathology, aDownloaded for Anonymous User (n/a) at The University of Edinbur
For personal use only. No other uses without permission. Ccohort of C57BL/6 and P301S mice were sacrificed 4
or 24 hours after injection. Serum collected 4 hours af-
ter injection was assayed for TNF-a and IL-1b. TNF-a
was below assay detection in all saline-injected ani-
mals (Fig. 3D) and IL-1b levels were reduced in
P301S relative to C57BL/6 mice (P , .001-Fig. 3E)
indicating that P301S tauopathy per se does not induce
systemic cytokines. TNF-a and IL-1b levels were
increased to similar degrees after LPS injection in
C57BL/6 and P301S mice (P , .001 for each ana-
lyte-Fig. 3D,E).gh from ClinicalKey.com by Elsevier on November 05, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Fig. 2. P301S mice display regional heterogeneity of microgliosis: Representative examples of IBA1-stained cortical tissue (A–D) and spinal cord (lamina 9)
(F–I) from a C57BL/6 mouse at 20 weeks, and P301Smice at 8, 12, and 20 weeks. Dotted line marks 150 mm subpial depth, and scale bar represents 100 mm (A–
D). Dotted line marks ventral horn, scale bar represents 200 mm, and in-lay scale bar represents 25 mm (F–I). (E) IBA11 cell counts conducted in themotor cortex
(to subpial depth of 150 mm) showed no difference between C57BL/6 and P301S mice at any age and no change over time. C57BL/6 n5 13, P301S 8 wk n5 4,
9 wk n5 3, 10 wk n5 6, 11 wk n5 5, 12 wk n5 5, 16 wk n5 6 20 wk n5 5. (J) IBA11 cell counts in lamina 9 of the spinal cord indicated regional microgliosis
in P301Smice from 10 weeks onward. Time-course analysis showed that microgliosis was progressive (increase of 15.5 IBA11 cells/mm2/week, P, .001; 95%
CI 11.1 to 19.8). C57BL/6 n5 15, P301S 8 wk n5 6, 9 wk n5 3, 10 wk n5 7, 11 wk n5 4, 12 wk n5 3, 16 wk n5 5; 20 wk n5 4. (K) The relative quantity of
ItgaxmRNA (P5 .007; 95% CI 0.2 to 1.2) but not Axl, Clec7a, and TyrobpmRNAwas elevated in P301S vs. C57BL/6 cortex. (L) All 4 genes were elevated in
the spinal cords of P301S compared with C57BL/6 mice: Axl (1.4-fold, P 5 .035; 95% CI 0.0 to 0.8), Itgax (14.9-fold, P, .001; 95% CI 9.9 to 17.8), Clec7a
(5.8-fold, P , .001; 95% CI 3.4 to 6.2), and Tyrobp (1.9-fold, P5 .014; 95% CI 0.2 to 1.4) (all groups n  8). Analyses were by mixed-effects LR; *P , .05,
**P , .01, ***P , .001. Abbreviation: LR, linear regression.
M. Torvell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 579-591584Il1b mRNA transcription in the motor cortex and spinal
cord of P301Smicewas not different fromC57BL/6 controls
(Fig. 3F); however, LPS injection increased Il1b 22.4-fold in
C57BL/6 mice (P, .001) compared with 9.5-fold in P301S
mice (P, .001). The interaction term indicated that LPS had
a significantly smaller impact on P301S mice than C57BL/6Downloaded for Anonymous User (n/a) at The University of Edinbur
For personal use only. No other uses without permission. Cmice (relative quantity 211.9; P 5 .002; 95% CI 218.7 to
25.0). The same trend was found in the spinal cord: Il1b
was equivalent in P301S mice and C57BL/6 mice
(Fig. 3G), while LPS injection increased Il1b, in both groups
and to a smaller degree in P301S mice (relative quantity
252.1; P 5 .023; 95% CI 296.1 to 28.14). These datagh from ClinicalKey.com by Elsevier on November 05, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Fig. 3. LPS injection caused an exaggerated acute behavioural and pathological response in P301S mice: (A) Horizontal bar performance of C57BL/6 ( ) is
stable throughout 10–21 weeks (0.0 D points/week; P 5 .728; 95% CI 20.1 to 0.1). P301S mice ( ) displayed a stable phase (10–16 weeks), followed by a
declining phase (16–21 weeks) during which they lost 0.9 points/week (P , .001; 95% CI 21.1 to 20.8) (up to 20 weeks: n 5 15/group; 21 weeks: n 5 12/
group). C57BL/6 and P301S mice were injected with LPS (i.p., 500 mg/kg) or saline at 10 or 16 weeks of age (indicated by grey lines). (B) Distance travelled in
the open-field chamber by LPS-injected mice is expressed as a percentage of distance travelled by saline-injected counterparts. Four hours after injection, LPS
M. Torvell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 579-591 585
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=M. Torvell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 579-591586suggest that microglia are not primed by tau exposure and
may even be desensitized.3.7. LPS injection increases tau pathology in P301S mice
To test whether LPS injection at 16 weeks acutely
increased tau pathology, AT81-neurons were counted.
C57BL/6 controls had no AT81-neurons in the motor cortex
regardless of LPS exposure (Fig. 3H–L); however, AT81-
cells were detected in the motor cortex and spinal cord of
P301Smice and were increased 24 hours after LPS treatment
in the motor cortex (Fig. 3H–L) and spinal cord (Fig. 3
M-Q).3.8. Systemic inflammation exacerbates the trajectory of
functional decline
After a single LPS injection, all groups of mice showed
impaired horizontal bar performance that recovered after
resolution of the acute sickness response (Fig. 3C). There-
after, C57BL/6 mice maintained baseline performance
throughout the rest of the experiment, regardless of whether
they were injected early or late with saline or LPS (Fig. 4).
LPS injection at 10-weeks did not statistically influence
long-term decline in P301S mice. By contrast, task perfor-
mance of P301S mice injected with LPS at 16 weeks fell
by w0.9 points/week between 16 and 22 weeks of age
(P , .001–Fig. 4). For clarity of presentation, data from 10
and 16 weeks were pooled in all groups except P301S1LPS,
as described previously. The statistical significance of the
accelerated decline was not dependent on pooling of data
(for nonpooled data, see Supplementary data). Therefore,
the underlying disease stage significantly influences the
impact of an acute systemic inflammatory insult.impacted open-field activity of C57BL/6 and P301S mice. Twenty-four hours afte
injected with LPS at 10 or 16 weeks had not: P301S1LPS (10 wk: ) travelled
18.9) and P301S1LPS (16 wk: ) travelled 43.9% less than saline-injected co
C57BL/61LPS n 5 18, P301S1saline n 5 16, P301S1LPS (10 wk) n 5 9, P301
formance 6 hours after injection in C57BL/6 and, to a greater degree, P301S mice
61LPS ( ):20.9 D points; P5 .02; 95% CI21.5 to20.4; P301S1LPS (10 wk)
( ): (25.2 D points; P , .001; 95% CI 26.0 to 24.4). At 24 hours after LPS in
(C57BL/61LPS ( ): P 5 n.s; P301S1LPS (10 weeks) ( ): 20.5 D points; P
P, .001; 95%CI23.8 to22.2). (C57BL/61saline n5 19, C57BL/61LPS n5 2
n5 7). Plasma TNF-a (D) and IL-1b (E) concentrations from C57BL/6 or P301S
injection. TNF-a levels were below detection in saline-injected animals but LPS
1290.3 Dpg/ml; *P , .001; 95% CI 222.3 to 358.3; P301S1LPS: 1352.3 D pg/
61LPS n 5 6, P301S1saline n 5 6, P301S1LPS n 5 4). (E) Plasma IL-1b wa
95% CI -112.8 to -45.8). LPS injection increased IL-1b levels for both genotyp
P301S1LPS: 1136.7 pg/ml; *P , .001; 95% CI 94.3 to 179.2) (n 5 6/group)
P301S compared to C57BL/6 mice. LPS injection increased Il1b in C57BL/6 m
P, .001; 95% CI 6.4 to 12.5). LPS had a significantly smaller impact on Il1b in P
of AT8-stained cortical tissue (H–K) and spinal cord (M–P) collected 24 hou
P301S1LPS mice. (L) AT81 cells were detected in the motor cortex (4.0 cells
P301S mice only (9.2 D cells/mm2; yP 5 .055; 95% CI 20.3 to 18.6) (C57BL/6
n 5 4). (Q) AT81 cells were detected in lamina 9 of the spinal cord (22.7 cells/
AT81 cells in P301S mice although this was not statistically significant (115.2
61saline n 5 3, C57BL/61LPS n 5 5, P301S1saline n 5 7, P301S1LPS n
**P , .005, ***P , .001. Abbreviations: LR, linear regression; LPC, lipopolysac
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exacerbated decline
Saline-injected P301S mice showed significantly greater
neuronal loss (NeuN) in the superficial layers of the cortex
and spinal cord compared with C57BL/6 mice (Fig. 5A–
D) at 22 weeks of age. LPS injection caused equivalent
loss of NeuN1-cells in the cortices of C57BL/6 mice and
P301S mice (Fig. 5A, B), but no losses were observed in
the spinal cord (Fig. 5C, D). IBA11-microglial counts in
the superficial layers of the cortex were not significantly
different between any of the groups (Fig. 5E, F). Conversely,
there was significant microgliosis in the spinal cord lamina 9
in P301S mice compared with controls (P , .001–Fig. 5G,
H), and LPS injection at 16 weeks significantly increased
microgliosis in P301S (but not control) spinal cords at
22 weeks (P 5 .003) (Fig. 5G, H).
No AT81-neurons were observed in the motor cortex or
spinal cord of C57BL/6 mice regardless of LPS exposure
(Fig. 5I, J); P301S mice had abundant AT81-cells in both re-
gions at 22 weeks (P, .001), but LPS treatment at 16 weeks
had no significant impact on AT81 numbers in either region.4. Discussion
We have shown that a single systemic inflammatory event
causes exaggerated acute functional deficits and accelerated
disease-associated functional decline in the P301S mouse
model of tauopathy, particularly when applied later in dis-
ease. This demonstrates that mice with aggregated tau pa-
thology become progressively more vulnerable to
deleterious consequences of acute inflammatory insults.
There was stark regional heterogeneity of microgliosis, pro-
gressive and robust in the spinal cord but absent in the cortex
despite presence of cortical tau aggregates and neuronal loss.r injection, LPS-injected C57BL/6 mice had recovered ( ), while P301S
51.1% less than saline-injected counterparts (P 5 .002; 95% CI 283.2 to
unterparts (P 5 .015; 95% CI 278.9 to 9.0). (C57BL/61saline n 5 18,
S1LPS (16 wk) n 5 7). (C) LPS significantly impacted horizontal bar per-
; the magnitude of the effect was not impacted by age at injection (C57BL/
( ):24.3 D points; P, .001; 95% CI25.0 to23.6, P301S1LPS (16 wk)
jection, there was a differential impact of age of injection for P301S mice
5 .155; 95% CI 21.1 to 0.2; P301S1LPS (16 weeks) ( ): 23.0 D points;
2, P301S1saline n5 21, P301S1LPS (10 wk) n5 13, P301S1LPS (16 wk)
mice injected with saline or LPS, at 16 weeks, were measured 4 hours after
injection increased TNF-a plasma levels in both groups (C57BL/61LPS:
ml; *P , .001; 95% CI 288.9 to 415.7). (C57BL/61saline n 5 6, C57BL/
s reduced in P301S mice versus C57BL/6 mice (-79.3 Dpg/ml; *P , .001;
es (C57BL/61LPS: 1120.4 Dpg/ml; *P , .001; 95% CI 86.9 to 153.9;
. (F) Il1b mRNA levels were not elevated in the cortex or spinal cord of
ice (22.4-fold; P , .001; 95% CI 16.2 to 26.4) and P301S mice (9.5-fold;
301S than C57BL/6 mice (n 5 6 for each group). Representative examples
rs after injection from C57BL/61saline, C57BL/61LPS, P301S1saline,
/mm2; P 5 .193; 95% CI 22.6 to 10.7). LPS increased AT81 number in
1saline n 5 3, C57BL/61LPS n 5 5, P301S1saline n 5 6, P301S1LPS
mm2; **P 5 .005; 95% CI 8.9 to 36.4) and LPS increased the number of
D cells/mm2 vs. P301S1saline; P 5 .147; 95% CI 26.6 to 36.9) (C57BL/
5 6). Scale bar 100 mm. Analyses were by mixed-effects LR; *P , .05,
charide.
gh from ClinicalKey.com by Elsevier on November 05, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Fig. 4. LPS injection in P301S mice at 16 weeks, but not 10 weeks, accel-
erates decline of horizontal bar performance. P301S mice injected with sa-
line ( ) showed a steady performance decline (0.9 points/week; P, .001;
95% CI21.0 to20.8). LPS injection at 16 weeks, but not 10 weeks of age,
accelerated decline in performance (P301S1LPS (10 wk) ( ): 10.1 D
points/week versus P301S1saline; P 5 .140; 95% CI 0.0 to 0.2;
P301S1LPS (16 wk) ( ): 20.5 D points/week versus P301S1saline;
P, .001; 95% CI 20.6 to 20.4). The differential impact of age at LPS in-
jection was significant when compared to C57BL/6 mice (21.2 points/
week; P , .001; 95% CI 21.3 to 21.0) and P301S mice (20.6 points/
week; P , .001; 95% CI 20.7 to 20.5) (20 weeks C57BL/61saline
n 5 21, C57BL/61LPS n 5 22, P301S1saline n 5 19, P301S1LPS
(10 wk) n 5 13, P301S1LPS (16 wk) n 5 7; 21–22 weeks: C57BL/
61saline n 5 18, C57BL/61LPS n 5 18, P301S1LPS (10 wk) n 5 9,
P301S1LPS (16 wk) n 5 7). Analyses were by mixed-effects LR. Abbre-
viations: LR, linear regression; LPS, lipopolysaccharide.
M. Torvell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 579-591 587Susceptibility to acute deficits and accelerated progression
was independent of microglial priming or IL-1b hyperex-
pression after LPS injection.
4.1. Systemic inflammation and exacerbation of disease
Severe sepsis can induce acute brain failure, evident as
delirium [27], permanent brain damage, and cognitive
dysfunction in man and mouse [28]. Rodents injected with
high-dose LPS to mimic severe sepsis developed CNS
inflammation, BBB breakdown, neuronal death, and cogni-
tive impairments [29–32]; however, precisely how these
inflammatory insults impact the trajectory of neurological
and functional decline is unknown. Here we show that a
systemic low-dose LPS injection at 10 or 16 weeks of age
caused an exaggerated, prolonged acute sickness response
in P301S mice compared with controls. Importantly, these
exaggerated acute symptoms extended beyond typical sick-
ness behaviours to include motor symptoms; performance
on the horizontal bar task was progressively impaired in
P301S mice in late disease due to tauopathy-induced neuro-
logical dysfunction (Fig. 1), but this feature was absent at the
time of LPS injection. Therefore, acute systemic inflamma-
tion unmasks disease-associated network vulnerability in
presymptomatic animals, mirroring findings in the ME7Downloaded for Anonymous User (n/a) at The University of Edinbur
For personal use only. No other uses without permission. Cmodel of prion disease [12,18]. Findings, in both models
support the idea that disease pathology progressively
depletes cognitive and/or functional reserve rendering
functions in those newly pathological regions vulnerable to
acute stressors like LPS. There is also support for this in
humans: baselineMini–Mental State Examination score cor-
relates strongly with delirium risk in older adults [18].
Although delirium is one major consequence of acute illness
in dementia, patients also show marked impairment of trunk
strength and motor function [33]. Given the vulnerability of
motor function in the tauopathy model, acute failure in mo-
tor function during LPS-induced systemic inflammation il-
lustrates a deleterious interaction of acute systemic
inflammation with disease pathology, the magnitude of
which is determined by the extent of the underlying pathol-
ogy at the time of the acute inflammatory episode.4.2. Microglia
We hypothesized that acute functional deficit might be
underpinned by microglial priming. Previous studies
demonstrated that microglial “priming” by primary neuropa-
thology produces an exaggerated IL-1b response to subse-
quent inflammatory challenge [34], a phenotype replicated
in multiple models [35–41], and shown by coexpression
meta-analysis to share a transcriptional profile among
several degenerative models, including the rTg4510 model
[42]. Analysis of microglia in the present study demon-
strated region-specific microgliosis: IBA11-microglial
number in the cortex was unchanged at each time point
analysed, even after LPS injection, while spinal cord
IBA11-microglia showed progressive increase in number,
morphological changes associated with activation, and
increased expression of Axl, Clec7a, and Itgax genes,
markers of primed microglia, and Tyrobp, a proxy for micro-
glial number [42]. Conversely, cortical microglia maintained
a ramified morphology throughout, and of the markers of
priming, only Itgax expression was slightly elevated. Micro-
glia exist on a spectrum of immune-vigilance along the
rostral-caudal axis, such that cortical microglia are subject
to stringent immune-regulation, whereas caudal microglia
are more readily activated [43,44]. Our data also support
work from pure tauopathy human postmortem studies
where spatiotemporal correlation between microglial
burden and pathological tau burden has been repeatedly
observed [45–47]. However, although the
immunohistochemical and transcriptional data demonstrate
a primed microglial profile in the spinal cord but not in the
cortex; upon systemic LPS challenge, neither region
showed exaggerated Il1b transcription typical of primed
microglia. Indeed, in both regions, Il1b transcription was
significantly reduced in LPS-treated P301S mice with
respect to LPS-treated controls, suggesting that microglia
in the P301S model are desensitized by exposure to tau
and/or degenerating neurons. Desensitization of microglia
can occur upon repeated inflammatory challenge [48], andgh from ClinicalKey.com by Elsevier on November 05, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Fig. 5. Systemic inflammation exacerbates end-stage pathology: Representative examples of NeuN-stained (A and C), IBA1-stained (E and G), and AT8-
stained (I and K) cortical and spinal cord tissue collected at 22 weeks of age from C57BL/61saline, C57BL/61LPS, P301S1saline, and P301S1LPS
mice. Scale bars represent 100 mm (A, C, I, K) or 50 mm (E, G). (B) NeuN1 cell counts in the motor cortex from C57BL/6 and P301S mice injected with either
saline or LPS demonstrated significant neuronal loss in P301S mice compared with controls (2283.1D cells/mm2 vs. C57BL/6; **P, .005; 95% CI2452.8 to
2113.5). LPS impacted NeuN1 cell counts in C57BL/6 mice, and P301S mice (*P, .05), but there was no significant difference between genotypes (C57BL/
61saline n 5 6, C57BL/61LPS n 5 7, P301S1saline n 5 4, P301S1LPS n 5 5). (D) NeuN1 cell counts in lamina 9 of the spinal cord showed significant
neuronal loss in P301S mice compared with controls (265.9 D cells/mm2; ***P, .001; 95% CI290.8 to241.0) but no effect of LPS on NeuN1 cell counts
(C57BL/61saline n5 8, C57BL/61LPS n5 8, P301S1saline n5 8, P301S1LPS n5 8). (F) IBA11 cell counts in the motor cortex 24 hours after injection
indicate that neither genotype nor LPS exposure significantly impacted microgliosis (C57BL/61saline n 5 6, C57BL/61LPS n 5 7, P301S1saline n 5 6,
P301S1LPS n 5 6). (H) IBA11 cell counts in the spinal cord lamina 9 demonstrate increased microgliosis in P301S compared to control mice (1218.7 D
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with terminal systemic infections also show an immunosup-
pressed phenotype [49]. Moreover, in AD tissue, hippocam-
pal microglia proximal to tau pathology showed a dystrophic
or degenerative profile which was partially replicated in
Thy1-tau22, but not APP/PS1mice [50] indicating that tau
does not affect microglia in the same way that amyloid-b
does.
By end stage (22 weeks), there was profound
microgliosis in the spinal cords of P301S mice, signifi-
cantly increased after LPS treatment at 16 weeks,
demonstrating that acute systemic inflammation drives
tauopathy-related pathology. Although it is clear that
tau can drive microgliosis [45–47,51–54], there is also
evidence that microgliosis drives tau pathology [15,55];
hence, it is conceivable that an acute increase in tau
pathology after LPS administration initiates a self-
perpetuating loop between microgliosis and increasing
tau pathology.4.3. Exacerbation of tau pathology and functional decline
by acute inflammation
A single LPS injection at 16 weeks acutely increased
AT81-tau hyperphosphorylation in the motor cortex and spi-
nal cords of P301S mice (Fig. 3H–Q). Transient tau hyper-
phosphorylation in response to systemic inflammation is
described even in wild-type mice [56]. In 3xTg-AD mice,
systemic LPS injection markedly increased tau hyperphos-
phorylation early in disease, mediated by dysregulation of
tau kinase CDK5 [14], and later in disease attributed to
GSK-3b activation [41]. In hTau transgenic mice, LPS-
induced tau hyperphosphorylation 24-hours after injection
was blocked in Tlr42/2 and Il-1r12/2 mice, implicating
both canonical TLR4 and IL-1RI signalling [15]. In the pre-
sent study, LPS induced robust Il1bmRNA expression in the
cortices and spinal cords of C57BL/6 and P301S mice.
Although Il1b expression was similar in P301S and
C57BL/6 mice, one might still speculate that IL-1b could
drive the observed exaggerated functional deficits: neurons
from the degenerating brain were significantly more sensi-
tive to IL-1b stimulation in other models [17]; hence, it is
plausible that IL-1b levels innocuous in the healthy brain
may damage neurons in disease. However, experiments in
IL-1R1-/- mice show cytokine redundancy in LPS-induced
neurological deficits; wild-type and IL-1R1-/- mice with
ME7 prion disease injected with LPS developed equivalent
sickness, weight loss, and acute working memory deficits
[17] suggesting that alternative LPS-induced inflammatorycells/mm2; ***P, .001; 95% CI 153.7 to 283.7), further increased in response to L
52.7 to 214.6 vs. 1 87.5 D cells/mm2; P 5 .061; 95% CI 24.4 to 179.3). C57BL/
n5 7. AT81 cells were detected in the motor cortex (J) and spinal cord (L) of P30
cord: 123.8 cells/mm2; P , .001; 95% CI 101.2 to 146.4). LPS did not impact th
*P , .05, **P , .005, ***P , .001. Abbreviations: LR, linear regression; LPS, l
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P301S mice.
4.4. Limitations and future work
This work has some limitations. Although we demon-
strate that a single inflammatory episode causes significant
alteration of disease course in a tauopathy model, we do
not provide a complete mechanistic explanation.We propose
contributions of proinflammatory cytokines, notably IL-1b
that merits further exploration in this model of tauopathy.
It is important to note that prior mechanistic studies of sys-
temic inflammation–induced disease exacerbation in mutant
tau models used higher LPS doses [15] or more numerous
LPS challenges (500 mg/kg 2x/week for 6 weeks [14,41]).
Therefore, our LPS dosing schedule, by design, likely
better mimics the impact of a single episode of illness
upon evolving tau-mediated pathology but it remains impor-
tant to clarify mechanistic underpinning of these exacerba-
tions. Moreover, it is now pressing to examine, in clinical
populations with tau-mediated pathologies, whether acute
inflammatory events such as infections, surgery, and inflam-
matory traumas produce acute changes in tau phosphoryla-
tion or other brain injury biomarkers that impact disease
course.
4.5. Concluding remarks
The notion that a single systemic inflammatory event can
produce acute functional deficits, can exacerbate disease-
associated pathology, and can hasten terminal functional
decline, shown here in P301S mice and supported in AD pa-
tients [10], illustrates the potential of acute illness to accel-
erate disease progression and emphasizes that there are
likely important therapeutic targets for slowing down pro-
gression of dementia that are tractable from outside the
CNS. Inflammation is a component of numerous preventable
medical conditions including hypertension, hypercholester-
olemia, diabetes, and obesity [8]; prevention or treatment
of which might reduce dementia incidence and improve
cognitive health with huge potential impact [57].
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1. Systematic review: The authors reviewed the litera-
ture using traditional methods to identify evidence
implicating systemic inflammation as a trigger of
acute and chronic behavioural and pathological ef-
fects in the context of neurodegeneration. This phe-
nomenon is described in dementia models and may
depend on microglial priming. Our study is the first
to examine functional decline in a pure tauopathy
neurodegeneration model.
2. Interpretation: Our findings support a significant
negative impact of a single systemic inflammatory
episode on subsequent disease course in the tauop-
athy model; inflammation was independent of micro-
glial priming. We conclude that systemic
inflammation exacerbates chronic decline in the
model.
3. Future directions: Themanuscript describes exagger-
ated neurological deficits induced by a single inflam-
matory episode; future work would prioritize
understanding the specific contributions of brain
endothelium, astrocytes, microglia, and infiltrating
immune cells and whether the observed deficits
result from intrinsic tau-mediated neuronal injury
or exaggerated extrinsic neuroinflammatory factors.References
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